JNC CORPORATION / MR SANGHAVI & CO. We are in the business of providing Biotech, Pharma, Fine Chemicals & Academia solutions. With state of the art chromatography bulk media, resins, gels & equipment’s from the world’s best companies, we offer the best technical solutions & support. The Cellufine™ product line offers a broad range of chromatography resins for the purification of proteins, enzymes, and biomolecules. The media based on spherical cellulose beads, exhibits high chemical stability / mechanical strength, higher flux and inherently bio-compatible. Applications include protein / polysaccharide purification, endotoxin removal, and used worldwide purifying vaccines, therapeutic enzymes, and virus concentration / purification. Cellulose media have significantly lower Leachable than comparable polymeric beads. Gel Filtration, IEX, Affinity, and HIC media available for broad range of biomolecules and applications. Cellufine customizes media / ligands, bead sizes for challenging purification process. Besides growing and consolidating the business of international marketing of industrial products and chemical specialties, we undertake backward/forward integration activity to produce tailor-made value-added specialty products. “Our mission is to become a benchmark organization in this line of business by striving consistently to develop our organization, professional skills & infrastructure as to be highly effective in this competitive environment.” Mr. Rajiv Sanghavi Director JNC CORPORATION/MR SANGHAVI & CO. 28, Sarvodaya Industrial Estate, Near Paper Box, Off. Mahakali Caves road, Andheri East, Mumbai – 400093 Mobile : +91-9323990409 Email : [email protected] Website : www.mrsanghavico.com
FedEx Express is the world's largest express transportation company, providing fast and reliable delivery to more than 220 countries and territories. FedEx Express uses a global air-and-ground network to speed delivery of time-sensitive shipments.
Connecting people with goods, services, and ideas creates opportunities and improves lives. At FedEx, we believe that a connected world is a better world, and that belief guides everything we do.
Consistently ranked among the world’s most admired and trusted employers, FedEx inspires its team members to remain focused on safety, the highest ethical and professional standards and the needs of their customers and communities. FedEx is committed to connecting people and possibilities around the world responsibly and resourcefully, with a goal to achieve carbon-neutral operations by 2040.
FedEx started operations in India as an independent carrier in 1997 and has since continued to play a crucial role in developing India’s express transportation industry. FedEx Express operates 38 weekly international cargo flights to and from India from Mumbai, Delhi, and Bangalore, connecting customers to our global air network. Today, FedEx Express continues to enhance its services and solutions in India, based on the needs of our customers, to offer unparalleled connectivity and access to global markets.
Sartorius Stedim Biotech is a leading partner of the biopharma industry. Our solutions support our customers in producing drugs safely, timely and economically. The key product categories of our company are cell cultivation, fermentation, filtration, purification, and fluid management.
Croda Pharma is a leading partner for the development of excipients and the supply of high purity materials for pharmaceutical formulations. Our drug delivery platforms provide tailored solutions to our customers to develop successful therapies. Ranging from small molecule and protein delivery, nucleic acid delivery through to adjuvant systems, our holistic approach in assisting in the success of drug formulation sets us apart. Providing support, application data, coupled with global manufacturing capabilities and collaboration opportunities make Croda Pharma the partner of choice for development success.
Combining our unique product portfolios and expertise, Croda Pharma and Avanti Polar Lipids are empowering the development and manufacturing of next generation vaccines. With strong expertise in high quality excipients, a culture of innovation and specialist scientific knowledge, we support our customers with the development of new and effective adjuvant systems and ingredients for vaccines.
To find out how we address the challenges of vaccine formulation and our offers, visit www.crodapharma.com.
Advanced Instruments is a global provider of scientific and analytical instruments for the bioprocessing and clinical industries. Since 1955, the company’s innovations have helped organizations improve quality of results, achieve reliable outcomes, and increase workplace productivity. Its newest addition, the Artel portfolio, includes leading analytical instruments, software and services that validate, automate, and calibrate critical liquid handling processes and instrumentation. In the biopharma space, the Solentim portfolio of best-in-class imaging and single-cell deposition technologies enables the clonal isolation, outgrowth, and characterization of the highest value cells for monoclonal antibody upstream development and cell and gene therapy. Its OsmoTECH® line of micro-osmometers are built specifically to support workflows throughout every phase of bioprocessing. Similarly, clinical labs worldwide rely on Advanced Instruments’ innovative solutions for delivery of accurate and timely patient results in their clinical chemistry, microbiology and hematology labs. For more information, visit www.aicompanies.com
With over 35 years’ experience as a global contract service organization, SGS provides integrated (bio)pharmaceutical development and testing solutions including clinical research, pharmaceutical development, biologics characterization, biosafety, and quality control testing for small and large molecules, raw materials, containers and finished products.
SGS provides a comprehensive range of biosafety services such as: virology, cell and molecular biology, microbiology and TEM. Health Authorities (US FDA and the EMA), require companies to undergo safety testing demonstrating that cell banks, viral banks, raw materials, bulk harvests, and batches of clinical drug are free of bacteria, fungi, mycoplasma, viruses and other potential contaminants. SGS ensures product safety in satisfying these regulatory requirements.
Datwyler is a leading industrial supplier and a key player in the global health care world.
Our state-of-the-art solutions for drug packaging and medical devices, build on over 100 years of experience. Within our healthcare offering, we provide a unique range of products and services including the most advanced elastomer formulations, coatings, aluminum
seals, and processing technologies. Partnering up with the world’s top pharmaceutical and medical companies, we are a vital link and stand by our mission to ensure all patient’s safety and improve patients’ lives.
For more infromation, please visit: https://datwyler.com/
Marken is a wholly owned subsidiary of UPS and is the essential clinical part of UPS Healthcare. With Marken, BOMI Group and Polar Speed included, the UPS Healthcare network staffs 199 locations with 10,000+ employees worldwide. Marken offers a state-of-the-art GMP-compliant depot network and logistic hubs for clinical drug product storage and distribution in 59 locations worldwide, while maintaining the leading position for Direct-to-Patient and Home Healthcare services, biological sample shipments and biological kit production. Marken’s dedicated 2,400+ staff members manage 154,000 drug product and biological sample shipments every month at all temperature ranges in more than 220 countries and territories and have orchestrated 14,000+ home healthcare visits. Additional services such as cell and gene supply chain services, ancillary material sourcing, storage and distribution, shipment lane verification and qualifications, as well as GDP, regulatory and compliance consultancy add to Marken’s unique position in the pharma and logistics industry.
Link to your website - https://www.marken.com/
Merck, a leading science and technology company, operates across life science, healthcare and
electronics. To the life science industry, we provide solutions and services for research,
biotechnology development and production, and pharmaceutical drug therapy development
The Millipore® portfolio of Merck offers an ecosystem of industry-leading products and
services, spanning preparation, separation, filtration, and monitoring, as well as clinical and
commercial biomanufacturing CTDMO services - all of which are deeply rooted in quality,
reliability and time-tested processes. The SAFC® portfolio of Merck offers customized and
ready-to-use raw material solutions, backed by deep regulatory expertise. Our proven products,
expert services and regulatory and application expertise are a strong foundation you can rely on
to consistently perform at the highest level.
For more information, please visit https://www.merckmillipore.com and
Nanghavi is a Joint Venture between Sweden based R&D company Nanologica and an Indian family owned business by the Sanghavi family, thereby deriving the name “NANGHAVI”.
We are in the business of manufacturing Analytical, Semi Preparative and Prep HPLC columns by. Our in-house capabilities boasts of manufacturing the silica, functionalizing it, packing the HPLC column & marketing and selling them.
We have an end-to-end capability of manufacturing from the raw material of spherical silica to the HPLC columns itself, we can have complete control over quality of the end product.
Terumo Pharmaceutical Solutions develops patient-oriented parenteral delivery solutions for therapeutic performance and safety Globally trusted for quality and precision, Terumo Pharmaceutical Solutions offers pharmaceutical and medical device manufacturers around the world comprehensive product design and development services, for primary container, injection, infusion therapy devices, and contract development and manufacturing services (CDMO).
We have decades of experience collaborating with pharmaceutical companies from the earliest phases of drug development to product commercialization to optimize critical aspects of parenteral
drug delivery. Innovation and creativity are central to our value proposition. Our expert teams lead the industry in developing and manufacturing advanced, high-performing infusion and injection technologies for
all parenteral applications. We provide sterile injectable contract development and manufacturing (CDMO) services from initial combination device design and formulation development to commercial manufacturing.
supporting better patient outcomes around the world.
We listen. We question. We deliver.
Unither Pharmaceuticals is a 30-year-old French CDMO and world-leader in sterile unit doses using Blow-Fill-Seal (BFS) technology to produce eye drops, saline solutions, and asthma medications. It has a capacity of 5 billion BFS doses with products sold in over 100 countries. Unither recently introduced Euroject®: an innovative BFS-based device for single dose injection of therapeutics, contributing to greater equity in access to vaccines and ensuring safe vaccine administration, while being user-friendly and cost-effective. It employs more than 2000 people in 8 manufacturing plants and R&D center in France, Brazil, China, and the US. Its turnover in 2022 was €371 million.
Elomatic, India is a turnkey engineering & consulting company dedicated to the pharmaceutical & biotech industry. It is a Joint Venture of Elomatic Oy, Finland. Elomatic is a multidiscipline industrial engineering, consulting, and software Design Company from Finland and the Pharmaceutical & Biotech sector is the key focused SBU of their process division.
Elomatic provides end to end engineering & consulting solutions starting from concept to commissioning. Broadly, it includes services like Conceptual design, Civil Structural & Architectural design, Basic engineering, Process engineering, Value engineering, Detailed engineering, Procurement assistance, Qualification documentation, FAT & Validation services along with Site management.
Pharmaceutical industries have stringent regulations when it comes to quality and safety.
In order for businesses to remain competitive in this industry, they need accurate and
fast microbial contamination detection solutions that are adaptable and cost-effective.
bioMérieux helps the pharmaceutical and healthcare industries unlock greater value from
their organizations through a complete line of diagnostic solutions that enable more rapid,
consistent results. Reliable and quick results improve safety, enhancing your brand
protection, and maintenance of safer pharmaceutical products. bioMérieux solutions
protect your product quality.
Since 1998, Ami Polymer is in the business of Silicone Elastomeric products and also, other Polymeric components which ultimately provide solutions to Fluid Transfers, Sealing, and Contamination controls for Biopharma, Pharma, Medical, Laboratory, Food, Beverages, and Engineering sectors worldwide. We Are Experts in Silicone Tubing, Hoses & Single-Use Assemblies.
Ami Polymer is having ISO Class VII and ISO Class VIII Cleanroom facilities certified with ISO 9001:2015, ISO 14001:2015, ISO 45001:2018, ISO 27001:2013, ISO 13485:2016. We also have a BPOG extractables program for our products for regulatory markets worldwide.
Everything began with a commitment to serve the life sciences and healthcare industries by offering global transport and innovative temperature-controlled logistics solutions. Being one of the market leaders in our sector and dedicated to the clinical trial and cell & gene therapy communities, we are operating in more than 150 countries intending to improve the health of people around the world. Truly focused on our customer and patient needs, we, through a dedicated team, plan, manage and implement a tailor-made temperature-controlled solution to fit your requirements and business goals. Count on us to deliver your life-saving goods worldwide - Count on CRYOPDP!
CRYOPDP video: https://www.youtube.
Pfanstiehl is the market leader of high purity, low endotoxin, low metal excipients for biologics, biosimilars, vaccines, cell culture media and injectable (liquid and lyophilized) formulations and supplies its products to nearly all leading global biopharmaceutical companies.
Pfanstiehl was founded in 1919 and currently celebrating its 103rd anniversary year in 2022. Pfanstiehl is headquartered at Waukegan, IL, USA and has diverse global technical support team across the globe in USA, Europe & APAC.
Pfanstiehl has manufactured parenteral grade excipients for more than 50 years, and Pfanstiehl’s high purity, low endotoxin and low metal excipient products are known as “best in class” due to their high characterization, performance, consistency, and quality attributes.
Pfanstiehl’s excipients are critical components in the majority of the global blockbuster biopharmaceutical drugs and vaccines including majority of the Covid -19 vaccines that were administered globally.
For more information about Pfanstiehl Inc, and their products and solutions, please contact us at [email protected] or visit www.Pfanstiehl.com
For more than 85 years, Kerry has provided integrated solutions for the world’s leading biotechnology customers. We are a global leader in innovation and applications for cell culture, diagnostic, and fermentation media. Every day we expand our capabilities to meet the changing needs of the biotech market. We provide cell nutrition supplements including protein hydrolysates, yeast extracts, recombinant proteins, and complex systems that maximize yields and cell performance in biotechnological production systems. We have the vast global resources and technical platform to deliver consistent, high-quality products backed by unparalleled service, technical support, and formulation customization capabilities
Elsevier, a global leader in information and analytics, helps researchers and healthcare professionals advance science and improve health outcomes for the benefit of society. We extract reliable data from scientific literatures to support corporate R&D professionals save time, make better decisions and innovate. Our life science solutions for pharmaceutical customers including, Reaxys, ScienceDirect, Scopus, Embase and Pharmapendium, which combine trusted data and analytics to help you answer critical drug discovery and business questions, including efficiently monitoring post-market drug safety literatures.
“PharmNXTBiotech is a young Biotech Start-up based in Mumbai, it was established in the year 2017 with the idea of creating end-to-end bioprocess solutions and providing niche technologies to help reduce manufacturing costs for critical lifesaving drugs.
We recently inaugurated PharmNXTEkuse our brand new state-of-the-art single manufacturing facility based in Pune, which houses end-to-end solutions for the biopharma, vaccines manufacturing and containment solutions.
With the vision of “Make in India for the World,” we are ready to showcase our Xelta range of Single Use 2D, 3D bags and NXTmix Levitating mixing solutions along with our hardware technologies for downstream processing.
For containment solutions, we have our Make in India products: Flexible Isolators, Rigid Isolators as well as Powder Transfer Bags to handle potent molecules.”
Clinical Research Network India (CRN India) (A Make In India CRO, Your Vaccine Research Partner)
· Clinical Research Network India (CRN India) is a Make in India CRO with extensive experience in Vaccines, Gene Therapy and Stem Cell Product Development Process.
· CRN India provides comprehensive solutions in Project Management, Medical Writing, Data Management, Regulatory Affairs, and other core research solutions.
· We are specialized in designing, conducting, and managing Phase I to Phase IV clinical trials.
· We have experienced in conducting following Vaccines, COVID Vaccines, Intranasal COVID Vaccines, Pneumococcal (Pediatrics & Adult), Rotavirus, Typhoid, Dengue, Tuberculosis, Malaria, Meningococcal, Japanese Encephalitis, HPV, MR, Oral Cholera, Hep-A, Varicella, Hexavalent, IPV and many more…
· The integration of resources at CRN India enables the highest level of quality research services with passion, knowledge, and integrity that makes it a global leader today.
Nucleus Network, Australia and USA’s Premier Phase I Specialists
Nucleus Network is the only Phase I clinical trial specialist with phase I units in both Australia and the United States. We have three units with 220+ beds and conduct a broad range of early phase clinical trials including FIH, DDI, TQT, Vaccine, Renal/Hepatic Impairment and Biosimilars.
The Australian clinical trial landscape allows global biotechs to advance their early phase clinical programs faster (Rapid Review cycles), easier (No IND), cheaper (43.5% Tax Incentive) and to the same quality standard (ICH/GCP) as studies performed in the USA.
We are Australia’s largest Phase I clinical trial provider with two clinics located in the major Australian cities of Melbourne and Brisbane enabling access to >50% (multiples more than any other Phase I group) of the population. Our large molecule Center of Excellence in Brisbane has been dedicated to development of New Biological Entities, Biosimilars and Vaccines for more than 20 years. This specialization leads to better recruitment outcomes for our sponsors and their programs.Our US clinic resides in the biotech hub of Minneapolis, Minnesota enabling us access to a total of more than 18 million people across all three sites.
Operating in the two global regions where a majority of Phase I studies are performed allows our sponsors to exceed their Phase I value inflection targets rapidly, efficiently and meet international quality standards allowing progression into Phase 2 and beyond.
Chris Hickey Executive Vice President Business Development
Chris has dedicated his 16-year career to the services side of the Phase I clinical drug development industry, including both operational and business development roles. Having worked within all major biopharma markets including USA, Japan, China, EU and Australia has enabled him to become a trusted advisor to many customers and help them achieve their clinical drug development objectives.
Chris’ deep knowledge of the global early phase drug development industry strengthens the tradition of success of Nucleus Network, our customers and partners in “Advancing Medicines, Improving Lives”.
Cell: (443) 685-5800
Centre for Cellular and Molecular Platforms (C-CAMP) is India’s premier innovation and technology hub and one of the largest and most vibrant life sciences incubators in the country. C-CAMP has directly funded, incubated and mentored 350+ start-ups over half a decade and is connected to over 2000 start-ups and entrepreneurs across the country in healthcare, agriculture and environment. C-CAMP has established 15 state-of-the-art technology platforms for facilitating cutting-edge research in the biosciences which have supported 230+ publications. C-CAMP is an initiative supported by Govt of India agencies including Department of Biotechnology, Department of Science & Technology, NITI Aayog-AIM, Ministry of Electronics and Information Technology, Startup India and Department of IT, BT, S&T Government of Karnataka. It has several international partnerships spread across US, UK, Netherlands, Denmark, Switzerland, Japan, Brazil and Israel.
The Vaccines World Summit 2023 is the premier vaccine conference dedicated to the Indian vaccine manufacturing sector. This event connects leaders in manufacturing, R&D and supply chain from vaccine manufacturing companies to debate best practices in vaccine manufacturing in India, share intelligence and network.
Addressing key hurdles to achieving rapid time to market efficiently, the conference illuminates the road forward for data usage, software and innovative solutions.
Dr Qlintang joined KALBE in 1999 and now leads in three of Kalbe's subsidiaries, namely Stem Cell and Cancer Institute, is a Kalbe’s Research, PharmaMetric Labs, is a CRO company and Bifarma Adiluhung, is a Stem Cell Manufacture with GMP certificate.
He is a reviewer member in Ministry of Research and Technology/National Research and Innovation Agency (Indonesia)since2019 and also member in Consortium of tissue engineering and stem cells, Ministry of Health since 2014, board member in Association of Indonesia Tissue Engineering and Cell Therapy since 2016 and member of Association of Indonesia’s Stem Cells since 2020.
Abhishek Mathur is currently working as the Chief Scientific Officer at Biolexis Pvt Ltd (A Strides Group Company), and is based in Bangalore, India. At Biolexis, Abhishek is responsible for leading CMC, Regulatory and Clinical strategy for end-to-end development and commercialization of biological therapeutics with special focus on regulated markets. In the role, Abhishek is also responsible for identifying in-licensing opportunities for early phase biological products & product cell lines, and developing a robust product pipeline for Biolexis. Abhishek has over 16 years of experience in leading biologics development at top tier biopharma companies like Amgen and Regeneron in the USA. During his stints in these organizations, he has successfully led multiple novel Biologics & Biosimilar programs from preclinical stage through commercialization. Further, in these roles he also established and led several strategic external partnerships with several CDMOs across the globe. Abhishek holds PhD in Biological Sciences from Northwestern University (USA), Bachelors of Technology in Chemical Engineering from IIT Bombay (India) and an MBA from Duke University (USA).
Parthasarathy Sampath Kumar
Currently working with Biocon Ltd based at Bangalore India, as Associate Vice President -Supply Chain responsible for Supply Planning, Inventory Management and Global Logistics.
Earlier worked with Ranbaxy Laboratories Ltd, Sentiss Pharma, TEVA API India, Jubilant Ltd.
A techno-commercial person and alumni of IIT Roorkee 88 batch with experience in Supply Chain, Logistics, Projects, Operations, Purchase, Commercial functions.
Capability to Train, Guide & Motivate team of professional, following path of Honesty and Integrity in all aspects of life. A regular speaker in various supply chain and logistics forums/seminars focusing on 5 I’s of futuristic supply chain and cold chain logistics.
Associated with Mission Safe Roads an NGO for safe roads for all of us.
Orhan Mutlu Topal
Libia Milena Hernandez
Dr. Harshad Shete is professionally trained in the field of pharmaceuticals, particularly in injectables, complex injectables, topical and peptide-based dosage forms. Graduated with a PhD in Pharmaceutics from Institute of Chemical Technology (ICT) where he focused on Cationic Lipid Nanoparticles (LNP) based Nucleic acid delivery, Dr. Harshad Shete continued to pursue his post-doctoral studies with Texas A & M University, strengthening expertise in formulation of biodegradable polymer-based nanoparticles for delivery of peptides and anticancer molecules and more.
With more than 8 years of working across various functions, Dr. Harshad Shete’s stints with notable industry players such as Novartis, Sun Pharma Advanced Research Company Ltd. and Cipla further honed his skillsets and sharpened his industry knowledge in CMOs, from application, technical operations, technology transfer, manufacturing to commercialization. To date, he has two patents, seven publications of international repute and several awards to his credit.
Swapan Kumar Jana
Rajinder Kumar Suri
Ravi P.N. Mishra
Vaccination programs save millions of lives each year globally. With more than 100 million children immunized each year, global immunization coverage has never been higher. Sources indicate that the worldwide market for vaccines is expected to reach USD 48.03 Billion by 2021 from USD 32.24 Billion in 2016 at a CAGR of 8.3% from 2016 to 2021. The key drivers driving the growth of this market are a high prevalence of diseases, rising government and nongovernment funding for vaccine development, increasing investments by companies, and increasing focus on immunization programs. With factors such as advances in immunology, genetics, and vaccine technology as well as increased demand from population growth in emerging economies, the global vaccine market is expected to surpass an estimated USD 100 billion by 2025. The economies of developing countries, for example, India is growing at a tremendous speed, and it is expected to grow 10-15% within the next decade. Emerging manufacturers play a critical role in the supply of vaccines of developing countries, particularly basic and some combination vaccines. 30% of UNICEF’s total procurement comes from emerging manufacturers. The decrease in vaccine prices can also be attributed to increased competition and higher production capacities for individual vaccines brought about by the entry of emerging market manufacturers, particularly in the underused vaccines market. Vaccines World Summit, for developing economies, aims to bring together key experts and decision-makers from vaccine manufacturers, governmental organizations, regulators, non-profit organizations, and solution providers together to aid in advancements in this industry with significantly higher collaboration.
COVID-19 Vaccine Action Plan in Asian Countries
Effective Strategies to Produce and Manufacture COVID-19 Vaccine at Scale and Pace
Ramping Up COVID-19 Vaccine Fill & Finish Capacity
Vaccines for Emerging Viral Diseases
Clinical Trial Results from Next- Gen and New Pipelines in the Industry
New Approaches to Evaluating Vaccine Quality Control & Safety
Production and Tech Transfers to Speed Up Local Vaccine Production
Whole-Microbe & Genetic Approach of Vaccine Development
The Way Forward for Vaccine Development and the Challenges Ahead
Standard Rate - End User
- 2- Day Conference Access
Standard Rate - Vendor
- 2- Day Conference Access
Enzene is an innovation-driven, technology-led differentiated biotech company from Pune, India, that manufactures Biosimilars and Novel Biologics for domestic and international markets.
Visit R&D Center in Pune India to experience the world class R&D infrastructure that allows access to technologies of the future.
Also, visit Enzene Biosciences Mammalian Manufacturing Unit in Pune, India to learn about the Continuous Bioprocess manufacturing at Enzene and how it can offer varied scientific support to the clients . You can understand how Enzene has end to end development platform from its own proprietary CHO duos cell lines to high throughput upstream and downstream platforms and how Enzene with its comprehensive drug product development capabilities backed by state-of-the-art advanced analytical technologies supports speedy development of pre-clinical and clinical drug candidates. Along with providing fully continuous end to end solutions, they also offer flexibility in terms of adapting to a fed-batch process.
Present your expertise to the key vaccines stakeholders from developing economies through a variety of available speaking packages.
Join the exhibition, and build an impressive presence among your potential clients.
Emphasize on your messages by promoting your brand alongside exhibition and thought leadership.
Engage with and build lasting connections that matter the most to your business.
Gain exclusive access to contacts of high-profile attendees through intimate networking opportunities.